Navigation Links
Many breast cancer patients take high doses of antioxidants despite possible consequences
Date:6/7/2009

A new study finds that many women with breast cancer take antioxidant supplements while undergoing cancer treatment, even though the consequences of doing so are unknown. Published in the July 15, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that additional research should be undertaken to determine the effects of antioxidant supplementation on the health and survival of breast cancer patients.

Antioxidant supplements include vitamin C, vitamin E, beta-carotene, and selenium. They are found in individual supplements as well as in many multivitamins. Many breast cancer patients believe that antioxidant supplements will protect them from the side effects of breast cancer treatment, help prevent breast cancer recurrence, and improve their overall health. However, the actual effects of taking antioxidants during cancer treatment are poorly understood and the findings to date are mixed. Some physicians believe antioxidants may in fact interfere with radiation and some types of chemotherapy, which often attacks tumor cells by generating reactive oxygen species (ROS), very small molecules that play a role in cell development.

Researchers led by Heather Greenlee, ND, PhD, Assistant Professor of Epidemiology and Medical Oncology (in Medicine) at Columbia University Mailman School of Public Health in New York, investigated the prevalence of antioxidant use in women with breast cancer who participated in the population-based Long Island Breast Cancer Study Project (LIBCSP). LIBCSP, which included more than 1,500 breast cancer patients, began as a federally mandated study that investigated whether breast cancer risk was associated with environmental exposures among women in Nassau and Suffolk counties in New York State. Dr. Greenlee's study is based on the 764 patients who completed a follow-up interview and provided information on antioxidant supplement use.

Among the 764 patients studied, 663 women (86.8 percent) reported receiving chemotherapy, radiation, or hormone therapy for breast cancer. Of these 663 women, six in ten (60.5 percent) reported using antioxidants during breast cancer treatment, which included chemotherapy, radiation, and tamoxifen (anti-estrogen) therapy.

About seven in ten antioxidant users (69.3 percent) used high doses, defined as higher than the dose contained in a Centrum multivitamin. Women who took high doses of antioxidants during treatment were more likely to be using tamoxifen and to have a history of eating more fruits and vegetables, using herbal products, and engaging in mind-body practices.

"Given the common use of antioxidant supplements during breast cancer treatment, often at high doses and in conjunction with other complementary therapies, future research should address the effects of antioxidant supplementation on breast cancer outcomes," including whether antioxidants affect treatment toxicities, treatment efficacy, cancer recurrence, and survival, say the authors.


'/>"/>

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society
Source:Eurekalert

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. MRI finds breast cancer before it becomes dangerous
3. Pathway links inflammation, angiogenesis and breast cancer
4. Drop in breast cancer incidence linked to hormone use, not mammograms
5. Breast cancer prevention practices vary across Canada
6. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
7. Acrylamide Wont Raise Breast Cancer Risk
8. New link between estrogen and breast cancer
9. Hypnosis Eases Pain of Breast Cancer Surgery
10. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
11. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... nation's first interactive health literacy software tool, and the Cancer Patient Education Network ... cancer patient education, today announce a new strategic alliance. , As CPEN’s ...
(Date:10/12/2017)... ... 12, 2017 , ... Vohra Chief Medical Officer Dr. Shark ... skilled nursing facility medical directors and other clinicians at various events in October. ... "At many of these conferences we get to educate other physicians, facility nurses, ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform ... published the first annual edition of its Global CSR Risk and Performance ... evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data ... ... ...
Breaking Medicine Technology: